Jeff Jones
Stock Analyst at Oppenheimer
(3.41)
# 962
Out of 5,241 analysts
97
Total ratings
35.63%
Success rate
8.88%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Outperform | $62 → $66 | $26.72 | +147.01% | 5 | May 15, 2026 | |
| PMVP PMV Pharmaceuticals | Maintains: Outperform | $6 → $5 | $1.29 | +287.60% | 6 | May 13, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $57 → $54 | $11.03 | +389.57% | 12 | May 13, 2026 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $10 | $4.52 | +121.24% | 1 | Apr 16, 2026 | |
| ALMS Alumis | Maintains: Outperform | $50 → $55 | $22.87 | +140.49% | 4 | Mar 30, 2026 | |
| PHAR Pharming Group | Reiterates: Outperform | $42 → $41 | $12.92 | +217.34% | 1 | Mar 13, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $32 → $33 | $12.31 | +168.07% | 7 | Mar 13, 2026 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $27.90 | +79.21% | 4 | Mar 6, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $82.21 | +45.97% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.66 | +1,406.02% | 9 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $17 | $4.72 | +260.17% | 4 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $86 | $28.05 | +206.60% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.96 | +354.55% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.09 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.85 | +315.58% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.15 | +3,813.04% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.64 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $4.75 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.74 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.11 | +88,762.56% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.92 | +27,961.22% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
May 15, 2026
Maintains: Outperform
Price Target: $62 → $66
Current: $26.72
Upside: +147.01%
PMV Pharmaceuticals
May 13, 2026
Maintains: Outperform
Price Target: $6 → $5
Current: $1.29
Upside: +287.60%
Corbus Pharmaceuticals Holdings
May 13, 2026
Maintains: Outperform
Price Target: $57 → $54
Current: $11.03
Upside: +389.57%
Aclaris Therapeutics
Apr 16, 2026
Initiates: Outperform
Price Target: $10
Current: $4.52
Upside: +121.24%
Alumis
Mar 30, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $22.87
Upside: +140.49%
Pharming Group
Mar 13, 2026
Reiterates: Outperform
Price Target: $42 → $41
Current: $12.92
Upside: +217.34%
Corvus Pharmaceuticals
Mar 13, 2026
Reiterates: Outperform
Price Target: $32 → $33
Current: $12.31
Upside: +168.07%
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $27.90
Upside: +79.21%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $82.21
Upside: +45.97%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.66
Upside: +1,406.02%
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $4.72
Upside: +260.17%
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $28.05
Upside: +206.60%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.96
Upside: +354.55%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.09
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.85
Upside: +315.58%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.15
Upside: +3,813.04%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.64
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $4.75
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.74
Upside: -
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.11
Upside: +88,762.56%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.92
Upside: +27,961.22%